Literature DB >> 19356464

Value of cardiovascular magnetic resonance stress perfusion testing for the detection of coronary artery disease in women.

Igor Klem1, Simon Greulich, John F Heitner, Han Kim, Holger Vogelsberg, Eva-Maria Kispert, Srivani R Ambati, Christian Bruch, Michele Parker, Robert M Judd, Raymond J Kim, Udo Sechtem.   

Abstract

OBJECTIVES: We wanted to assess the value of cardiovascular magnetic resonance (CMR) stress testing for evaluation of women with suspected coronary artery disease (CAD).
BACKGROUND: A combined perfusion and infarction CMR examination can accurately diagnose CAD in the clinical setting in a mixed gender population.
METHODS: We prospectively enrolled 147 consecutive women with chest pain or other symptoms suggestive of CAD at 2 centers (Duke University Medical Center, Robert-Bosch-Krankenhaus). Each patient underwent a comprehensive clinical evaluation, a CMR stress test consisting of cine rest function, adenosine-stress and rest perfusion, and delayed-enhancement CMR infarction imaging, and X-ray coronary angiography within 24 h. The components of the CMR test were analyzed visually both in isolation and combined using a pre-specified algorithm. Coronary artery disease was defined as stenosis > or =70% on quantitative analysis of coronary angiography.
RESULTS: Cardiovascular magnetic resonance imaging was completed in 136 females (63.0 +/- 11.1 years), 37 (27%) women had CAD on coronary angiography. The combined CMR stress test had a sensitivity, specificity, and accuracy of 84%, 88%, and 87%, respectively, for the diagnosis of CAD. Diagnostic accuracy was high at both sites (Duke University Medical Center 82%, Robert-Bosch-Krankenhaus 90%; p = 0.18). The accuracy for the detection of CAD was reduced when intermediate grade stenoses were included (82% vs. 87%; p = 0.01 compared the cutoff of stenosis > or =50% vs. > or =70%). The sensitivity was lower in women with single-vessel disease (71% vs. 100%; p = 0.06 compared with multivessel disease) and small left ventricular mass (69% vs. 95%; p = 0.04 for left ventricular mass < or =97 g vs. >97 g). The latter difference was even more significant after accounting for end-diastolic volumes (70% vs. 100%; p = 0.02 for left ventricular mass indexed to end-diastolic volume < or =1.15 g/ml vs. >1.15 g/ml).
CONCLUSIONS: A multicomponent CMR stress test can accurately diagnose CAD in women. Detection of CAD in women with intermediate grade stenosis, single-vessel disease, and with small hearts is challenging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19356464     DOI: 10.1016/j.jcmg.2008.03.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  24 in total

1.  Detection of coronary artery disease in postmenopausal women: the significance of integrated stress imaging tests in a 4-year prognostic study.

Authors:  Michael Becker; Anne Hundemer; Christian Zwicker; Ertunc Altiok; Thomas Krohn; Felix M Mottaghy; Christina Lente; Malte Kelm; Nikolaus Marx; Rainer Hoffmann
Journal:  Clin Res Cardiol       Date:  2014-11-01       Impact factor: 5.460

Review 2.  The NICE guidelines on the assessment of chest pain.

Authors:  Khaled Alfakih; Sven Plein
Journal:  J R Soc Med       Date:  2012-05       Impact factor: 5.344

3.  Postpartum unmasking of a severe triple-vessel-disease with acute myocardial infarction.

Authors:  Wilma Rademacher; Alexander Lauten; Angela Lauten; Andreas Ragoschke-Schumm; Hans Reiner Figulla
Journal:  Clin Res Cardiol       Date:  2010-04-21       Impact factor: 5.460

4.  Stress myocardial perfusion imaging by CMR provides strong prognostic value to cardiac events regardless of patient's sex.

Authors:  Otavio R Coelho-Filho; Luciana F Seabra; François-Pierre Mongeon; Shuaib M Abdullah; Sanjeev A Francis; Ron Blankstein; Marcelo F Di Carli; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  JACC Cardiovasc Imaging       Date:  2011-08

Review 5.  Assessment of myocardial ischemia with cardiovascular magnetic resonance.

Authors:  Bobak Heydari; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  Prog Cardiovasc Dis       Date:  2011 Nov-Dec       Impact factor: 8.194

Review 6.  Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease.

Authors:  Lauren A Baldassarre; Subha V Raman; James K Min; Jennifer H Mieres; Martha Gulati; Nanette K Wenger; Thomas H Marwick; Chiara Bucciarelli-Ducci; C Noel Bairey Merz; Dipti Itchhaporia; Keith C Ferdinand; Carl J Pepine; Mary Norine Walsh; Jagat Narula; Leslee J Shaw
Journal:  JACC Cardiovasc Imaging       Date:  2016-04

7.  Gender-based prognostic value of pharmacological cardiac magnetic resonance stress testing: head-to-head comparison of adenosine perfusion and dobutamine wall motion imaging.

Authors:  Cosima Jahnke; Vesna Furundzija; Rolf Gebker; Robert Manka; Michael Frick; Bernhard Schnackenburg; Nikolaus Marx; Ingo Paetsch
Journal:  Int J Cardiovasc Imaging       Date:  2011-07-06       Impact factor: 2.357

8.  Reproducibility of myocardial perfusion reserve - variations in measurements from post processing using commercially available software.

Authors:  Pavel Goykhman; Puja K Mehta; Megha Agarwal; Chrisandra Shufelt; Piotr J Slomka; Yuching Yang; Yuan Xu; Leslee J Shaw; Daniel S Berman; Noel Bairey Merz; Louise E J Thomson
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 9.  Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease.

Authors:  Michèle Hamon; Georges Fau; Guillaume Née; Javed Ehtisham; Rémy Morello; Martial Hamon
Journal:  J Cardiovasc Magn Reson       Date:  2010-05-19       Impact factor: 5.364

10.  Direct comparison of rest and adenosine stress myocardial perfusion CT with rest and stress SPECT.

Authors:  David R Okada; Brian B Ghoshhajra; Ron Blankstein; Jose A Rocha-Filho; Leonid D Shturman; Ian S Rogers; Hiram G Bezerra; Ammar Sarwar; Henry Gewirtz; Udo Hoffmann; Wilfred S Mamuya; Thomas J Brady; Ricardo C Cury
Journal:  J Nucl Cardiol       Date:  2010 Jan-Feb       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.